NIH Could Get Royalties, Not Input On Pricing, From R&D Investments, Collins Says

Federal funding for research and development of drugs can garner royalties for the U.S. Treasury but does not provide leverage to affect pricing decisions, National Institutes of Health Director Francis Collins told a Senate appropriations subcommittee May 11.